KNSA logo

Kiniksa Pharmaceuticals, Ltd. Class A Common Stock


KNSA: Kiniksa Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; Vixarelimab; and KPL-404.


Show KNSA Financials

Consumer Interest
SEC Filings

Recent trades of KNSA by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard

Recently reported changes by institutional investors

Quarterly net insider trading by KNSA's directors and management

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

Quiver Logo

No new patents for this ticker

U.S. Patents Dashboard
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard

Number of mentions of KNSA in WallStreetBets Daily Discussion


Recent insights relating to KNSA

CNBC Recommendations

Recent picks made for KNSA stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in KNSA

Corporate Flights

Flights by private jets registered to KNSA